Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 17,392 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 17,392 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $18.16, for a total value of $315,838.72. Following the sale, the chief operating officer directly owned 205,141 shares in the company, valued at $3,725,360.56. This trade represents a 7.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, January 22nd, Ryan Cohlhepp sold 3,828 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.10, for a total transaction of $69,286.80.
• On Thursday, January 15th, Ryan Cohlhepp sold 149 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.02, for a total transaction of $2,684.98.
• On Monday, December 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.68, for a total transaction of $233,500.00.

Bicara Therapeutics Stock Up 0.8%

NASDAQ BCAX traded up $0.14 during trading hours on Friday, hitting $18.64. 84,025 shares of the company were exchanged, compared to its average volume of 484,864. Bicara Therapeutics Inc. has a 52 week low of $7.80 and a 52 week high of $19.71. The stock has a 50-day moving average price of $16.43 and a 200 day moving average price of $15.70. The stock has a market cap of $1.02 billion, a PE ratio of -8.32 and a beta of -0.78.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BCAX. Wedbush reissued an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. HC Wainwright reiterated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Citizens Jmp started coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They issued a “market perform” rating and a $31.00 price target on the stock. Finally, Mizuho upgraded shares of Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.33.

Institutional Trading of Bicara Therapeutics

Large investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd boosted its holdings in Bicara Therapeutics by 385.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after buying an additional 4,585 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Bicara Therapeutics by 596.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after acquiring an additional 2,771,868 shares during the period. Invesco Ltd. boosted its stake in shares of Bicara Therapeutics by 20.6% during the 4th quarter. Invesco Ltd. now owns 21,006 shares of the company’s stock worth $354,000 after acquiring an additional 3,595 shares in the last quarter. VARCOV Co. acquired a new stake in shares of Bicara Therapeutics during the 4th quarter valued at about $263,000. Finally, Virtus Investment Advisers LLC increased its stake in shares of Bicara Therapeutics by 46.4% in the 4th quarter. Virtus Investment Advisers LLC now owns 14,395 shares of the company’s stock valued at $242,000 after purchasing an additional 4,560 shares in the last quarter.

Key Headlines Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Neutral Sentiment: Company announced an inducement equity grant under Nasdaq Rule 5635(c)(4) — a routine hire-related award but one that can create modest dilution expectations. Bicara Therapeutics Announces Inducement Grant
• Neutral Sentiment: Short-interest entries posted for early March report “large increases” but show 0 shares/NaN changes — this appears to be a data error and is not informative about genuine shorting pressure.
• Negative Sentiment: CFO Ivan Hyep sold a total of 16,518 shares across March 3–4 at ~ $18.22–$18.25, reducing his stake (~2–8.5% reductions in separate filings). Large, disclosed CFO sales can weigh on sentiment. Ivan Hyep SEC Form 4
• Negative Sentiment: COO Ryan Cohlhepp sold 17,392 shares on March 3 at an average ~$18.16 (~7.8% reduction). Significant sales by operating leadership can signal personal liquidity-taking and may pressure the stock. Ryan Cohlhepp SEC Form 4
• Negative Sentiment: Insider David Raben sold ~16,500 shares in two transactions (200 and 16,300 shares) at ~ $18.45–$18.52, representing a ~22.8% reduction in one filing. Large founder/executive selling is commonly viewed negatively by the market. David Raben SEC Form 4

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.